What is GDC-229 used for?

GDC-229 is indicated for Metastatic triple-negative breast cancer.

GDC-229 is developed by Balmoral Medical company.

What are the side effects of GDC-229?

Common side effects include Hyperglycemia, Diarrhea, Nausea.

Last reviewed 2026-04-23 · How we verify

GDC-229

Balmoral Medical company · Phase 3 active Small molecule

GDC-229 is a small molecule targeting the PI3K pathway.

GDC-229 is a small molecule targeting the PI3K pathway. Used for Metastatic triple-negative breast cancer.

At a glance

Generic name	GDC-229
Sponsor	Balmoral Medical company
Drug class	PI3K inhibitor
Target	PI3K
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

GDC-229 works by inhibiting the PI3K enzyme, which is involved in cell signaling pathways. This inhibition can lead to the reduction of cancer cell growth and proliferation.

Approved indications

Metastatic triple-negative breast cancer

Common side effects

Hyperglycemia
Diarrhea
Nausea

Key clinical trials

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GDC-229 CI brief — competitive landscape report
GDC-229 updates RSS · CI watch RSS
Balmoral Medical company portfolio CI